title: The PHEX transgene corrects mineralization defects in 9-month-old hypophosphatemic mice.
abstract: Hypophosphatemia is an X-linked dominant disorder resulting from a mutation in the PHEX gene. While osteoblast-specific expression of the PHEX transgene has been reported to decrease the phosphate wasting associated with the disease in male hypophosphatemic (HYP) mice, there are reports that the mineralization defect is only partially corrected in young animals. To test the hypothesis that osteoblast-specific expression of the PHEX gene for a longer time would correct the mineralization defect, this study examined the bones of 9-month-old male and female HYP mice and their wild-type controls with or without expression of the transgene under a collagen type I promoter. Serum phosphate levels, alkaline phosphatase activity, and FGF23 levels were also measured. Mineral analyses based on wide-angle X-ray diffraction, Fourier transform-infrared (FT-IR) spectroscopy, and FT-IR imaging confirmed the decreased mineral content and increased mineral crystal size in male HYP humerii compared to wild-type males and females with or without the transgene and in female HYP mice with or without the transgene. There was a significant increase in mineral content and a decrease in crystallinity in the HYP males' bones with the transgene, compared to those without. Of interest, expression of the transgene in wild-type animals significantly increased the mineral content in both males and females without having a detectable effect on crystallinity or carbonate content. In contrast to the bones, based on micro-computed tomography and FT-IR imaging, at 9 months there were no significant differences between the HYP and the WT teeth, precluding analysis of the effect of the transgene.
authors.affiliation: Musculoskeletal Integrity Program, Hospital for Special Surgery, Weill Medical College, Cornell University, 535 East 70th Street, New York, NY 10021, USA. Boskeya@hss.edu
authors.forename: Adele
authors.initials: A
authors.lastname: Boskey
authors.forename: Aaron
authors.initials: A
authors.lastname: Frank
authors.forename: Yukiji
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: Lyudmila
authors.initials: L
authors.lastname: Spevak
authors.forename: Kostas
authors.initials: K
authors.lastname: Verdelis
authors.forename: Bruce
authors.initials: B
authors.lastname: Ellis
authors.forename: Nancy
authors.initials: N
authors.lastname: Troiano
authors.forename: William
authors.initials: W
authors.lastname: Philbrick
authors.forename: Thomas
authors.initials: T
authors.lastname: Carpenter
mesh_terms: D000818:Animals; D015519:Bone Density; D002113:Calcification, Physiologic / Q000235:genetics*; D004195:Disease Models, Animal; D005260:Female; D000089703:Fibroblast Growth Factor-23; D017674:Hypophosphatemia / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D010018:Osteomalacia / Q000378:metabolism / Q000473:pathology; D053402:PHEX Phosphate Regulating Neutral Endopeptidase / Q000235:genetics* / Q000378:metabolism; D017550:Spectroscopy, Fourier Transform Infrared; D019076:Transgenes; D014961:X-Ray Diffraction
chemical_list: C000717428:Fgf23 protein, mouse; D000089703:Fibroblast Growth Factor-23; D053402:PHEX Phosphate Regulating Neutral Endopeptidase